Science

Elizabeth McKenna: PGV001 in Patients with Solid and Hematological Malignancies

Elizabeth McKenna/X

Mar 24, 2025, 13:36

Elizabeth McKenna: PGV001 in Patients with Solid and Hematological Malignancies

Elizabeth McKenna, Executive Director of Cancer Discovery at the American Association for Cancer Research, shared an article by Mansi Saxena, et al. on X:

“Now in Cancer Discovery:

PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform:

Phase I Study in Patients with Solid & Hematological Malignancies in the Adjuvant Setting – by Mansi Saxena, Tom Marron, Philip Friedlander, Alex rubinsteyn, Bhardwaj Lab, et al.”

PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematological malignancies in the adjuvant setting.

Authors: Mansi Saxena, et al.

Elizabeth McKenna: PGV001 in Patients with Solid and Hematological Malignancies

AACR alex rubinsteyn American Association for Cancer Research Bhardwaj Lab cancer Cancer Discovery Elizabeth McKenna fight against cancer Global fight against cancer hematological malignancies Mansi Saxena OncoDaily Oncology PGV001 Philip Friedlander Tom Marron

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial